Pliant Therapeutics, Inc. (PLRX)
NASDAQ: PLRX · Real-Time Price · USD
1.130
0.00 (0.00%)
Jun 25, 2026, 4:00 PM EDT - Market closed
Pliant Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 22.19 | 45.45 | 71.19 | 63.23 | 33.69 | 51.67 |
Short-Term Investments | 148.7 | 145.5 | 284.54 | 431.01 | 297.5 | 148.93 |
Cash & Short-Term Investments | 170.89 | 190.94 | 355.72 | 494.25 | 331.19 | 200.6 |
Cash Growth | -44.09% | -46.32% | -28.03% | 49.23% | 65.10% | -27.56% |
Accounts Receivable | - | - | - | - | 1.98 | 2 |
Other Receivables | - | - | - | - | 0.08 | 0.08 |
Total Trade Receivables | - | - | - | - | 2.07 | 2.08 |
Other Current Assets | 4.04 | 5.5 | 6.54 | 11.26 | 7.06 | 6.76 |
Total Current Assets | 174.93 | 196.45 | 362.26 | 505.5 | 340.31 | 209.44 |
Net Property, Plant & Equipment | 25.8 | 26.91 | 32.77 | 4.78 | 9.91 | 10.94 |
Other Long-Term Assets | 1.87 | 1.87 | 1.92 | 1.87 | 0.39 | 0.84 |
Total Assets | 202.6 | 225.23 | 396.95 | 512.15 | 350.61 | 221.22 |
Accounts Payable | 0.36 | 0.48 | 5.96 | 4.53 | 1.58 | 2.97 |
Accrued Expenses | 8.28 | 14.44 | 26.72 | 22.68 | 19.88 | 11.99 |
Current Portion of Leases | 1.71 | 1.45 | 0.54 | 1.32 | 2.46 | 1.87 |
Total Current Liabilities | 10.36 | 16.37 | 33.22 | 28.52 | 23.91 | 16.83 |
Long-Term Debt | - | - | 30.21 | 10.05 | 9.93 | - |
Long-Term Leases | 27.07 | 27.66 | 29.44 | - | 3.43 | 5.33 |
Total Long-Term Liabilities | 27.07 | 27.66 | 59.65 | 10.05 | 13.36 | 5.33 |
Total Liabilities | 37.43 | 44.02 | 92.87 | 38.58 | 37.27 | 22.16 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
Additional Paid-in Capital | 1,045 | 1,041 | 1,014 | 972.97 | 653.71 | 414.35 |
Accumulated Other Comprehensive Income | -0.34 | -0.02 | 0.32 | 0.35 | -1.96 | -0.2 |
Retained Earnings | -879.44 | -859.4 | -710.05 | -499.75 | -338.41 | -215.09 |
Shareholders' Equity | 165.17 | 181.21 | 304.08 | 473.58 | 313.34 | 199.06 |
Total Liabilities & Equity | 202.6 | 225.23 | 396.95 | 512.15 | 350.61 | 221.22 |
Total Debt | 28.78 | 29.11 | 60.19 | 11.37 | 15.82 | 7.19 |
Net Cash (Debt) | 142.11 | 161.84 | 295.53 | 482.87 | 315.37 | 193.4 |
Net Cash Growth | -12.19% | -45.24% | -38.80% | 53.11% | 63.07% | -30.15% |
Net Cash Per Share | 2.31 | 2.64 | 4.88 | 8.22 | 7.51 | 5.39 |
Book Value | 165.17 | 181.21 | 304.08 | 473.58 | 313.34 | 199.06 |
Book Value Per Share | 2.69 | 2.95 | 5.02 | 8.07 | 7.46 | 5.55 |
Tangible Book Value | 165.17 | 181.21 | 304.08 | 473.58 | 313.34 | 199.06 |
Tangible Book Value Per Share | 2.69 | 2.95 | 5.02 | 8.07 | 7.46 | 5.55 |